In last trading session, NewAmsterdam Pharma Company NV (NASDAQ:NAMS) saw 0.39 million shares changing hands with its beta currently measuring 0.08. Company’s recent per share price level of $20.18 trading at -$0.62 or -2.98% at ring of the bell on the day assigns it a market valuation of $1.86B. That closing price of NAMS’s stock is at a discount of -30.57% from its 52-week high price of $26.35 and is indicating a premium of 55.9% from its 52-week low price of $8.90. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.0 million shares which gives us an average trading volume of 398.11K if we extend that period to 3-months.
For NewAmsterdam Pharma Company NV (NAMS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.49 in the current quarter.
NewAmsterdam Pharma Company NV (NASDAQ:NAMS) trade information
Upright in the red during last session for losing -2.98%, in the last five days NAMS remained trading in the green while hitting it’s week-highest on Monday, 11/25/24 when the stock touched $20.18 price level, adding 6.83% to its value on the day. NewAmsterdam Pharma Company NV’s shares saw a change of 80.66% in year-to-date performance and have moved 0.30% in past 5-day. NewAmsterdam Pharma Company NV (NASDAQ:NAMS) showed a performance of 12.11% in past 30-days. Number of shares sold short was 1.01 million shares which calculate 2.62 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 37 to the stock, which implies a rise of 45.46% to its current value. Analysts have been projecting 36 as a low price target for the stock while placing it at a high target of 45. It follows that stock’s current price would drop -78.39% in reaching the projected high whereas dropping to the targeted low would mean a loss of -78.39% for stock’s current value.
NewAmsterdam Pharma Company NV (NAMS) estimates and forecasts
Statistics highlight that NewAmsterdam Pharma Company NV is scoring comparatively lower than the scores of other players of the relevant industry. The company added 7.63% of value to its shares in past 6 months, showing an annual growth rate of 3.72% while that of industry is 16.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 134.84% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 1.63M for the same.
NewAmsterdam Pharma Company NV (NASDAQ:NAMS)’s Major holders
Insiders are in possession of 0.25% of company’s total shares while institution are holding 89.54 percent of that, with stock having share float percentage of 89.77%. Investors also watch the number of corporate investors in a company very closely, which is 89.54% institutions for NewAmsterdam Pharma Company NV that are currently holding shares of the company.
On the other hand, PGIM Jennison Health Sciences Fd and Fidelity Select Portfolios – Pharmaceuticals are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 489.12 shares of worth $9.71 million or 0.53% of the total outstanding shares. The later fund manager was in possession of 330.2 shares on Sep 30, 2024 , making its stake of worth around $6.55 million in the company or a holder of 0.36% of company’s stock.
